Phase 1b Study of Axatilimab (CSF1R mAb) in Metastatic TNBC

This open-label, single-arm trial evaluates the combination of pembrolizumab, radiotherapy, and axatilimab for patients with metastatic or recurrent TNBC who have received prior immunotherapy. Conducted in Los Angeles and sponsored by Stephen Shiao, the study aims to assess safety and early efficacy by targeting myeloid suppression in a post-immunotherapy setting.